Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

NNZ-3006 shows fat reduction capabilities in animal model

Oct. 4, 2006

E.U. filing for febuxostat in symptomatic hyperuricemia accepted for review

Oct. 3, 2006

NDA submission for EvaMist

Oct. 3, 2006

Merck & Co. revises filing plans for MK-0524B

Oct. 3, 2006

Novel GSK-3 inhibitor increases trabecular bone mass in mice

Oct. 3, 2006

Novel chloride CIC-7 channel inhibitor PB-5430 reduces bone resorption in OVX rats

Oct. 3, 2006

Preclinical antidiabetic efficacy of AS100-244, a novel recombinant globular domain of adiponectin

Oct. 3, 2006

Selective thyroid beta agonist QRX-431 studied in phase I

Oct. 2, 2006

Ortho-McNeil extends research term in Arena GDIR partnership

Oct. 2, 2006

Inhaled insulin delivery systems discussed at the recent EASD meeting

Oct. 2, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...